Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.

ABSTRACT: BACKGROUND:While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite instability (MSI) are thought likely to respond favorably. To date, there is limited published data on this biologically distinct and clinically relevant subgroup's natural history and response to treatment. METHODS:We retrospectively identified patients at two academic institutions who had MMRd/MSI-high metastatic prostate cancer (PC). Clinical and pathologic characteristics at the time of diagnosis as well as response to standard therapies and immune checkpoint therapy were abstracted. Descriptive statistics, including PSA50 response (≥50% d

SUBMITTER: Graham LS 

PROVIDER: S-EPMC7250457 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature